Inhibrx Biosciences (INBX) Change in Receivables (2023 - 2025)
Inhibrx Biosciences (INBX) reported Change in Receivables of $226000.0 for Q4 2025, down 62.83% year-over-year from $608000.0 in Q4 2024, and up 277.95% quarter-over-quarter from -$127000.0 in Q3 2025.
Inhibrx Biosciences (INBX) Change in Receivables (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Change in Receivables data on file, last reported at $226000.0 in Q4 2025.
- Change in Receivables for Q4 2025 came in at $226000.0, down 62.83% year-over-year; the trailing twelve-month figure through Dec 2025 was -$20000.0 (down 110.81% YoY), and the FY2025 annual result was -$20000.0, down 110.81% from the prior year.
- Change in Receivables rose to $226000.0 in Q4 2025 per INBX's latest filing, from -$127000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $608000.0 in Q4 2024 and troughed at -$768000.0 in Q3 2024.
- A 3-year average of $68444.4 and a median of $64000.0 in 2025 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2024 and 2025: Change in Receivables sank 19300.0% in 2024, then soared 83.46% in 2025.
- A 3-year view of Change in Receivables shows it stood at $447000.0 in 2023, then surged by 36.02% to $608000.0 in 2024, then sank by 62.83% to $226000.0 in 2025.
- Business Quant data shows INBX's Change in Receivables at $226000.0 in Q4 2025, -$127000.0 in Q3 2025, and $64000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Inhibrx Biosciences | 186.16 Mn | 186.16 Mn | - | 226,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 226,000.00 |
| Dec 31, 2025 | 226,000.00 |
| Sep 30, 2025 | -127,000.00 |
| Sep 30, 2025 | -127,000.00 |
| Jun 30, 2025 | 64,000.00 |
| Jun 30, 2025 | 64,000.00 |
| Mar 31, 2025 | -183,000.00 |
| Mar 31, 2025 | -183,000.00 |
| Dec 31, 2024 | 608,000.00 |
| Dec 31, 2024 | 608,000.00 |
| Sep 30, 2024 | -768,000.00 |
| Sep 30, 2024 | -768,000.00 |
| Jun 30, 2024 | 345,000.00 |
| Jun 30, 2024 | 345,000.00 |
| Dec 31, 2023 | 447,000.00 |
| Dec 31, 2023 | 447,000.00 |
| Sep 30, 2023 | 4,000.00 |
| Sep 30, 2023 | 4,000.00 |